JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M203495200 on May 28, 2002

J. Biol. Chem., Vol. 277, Issue 33, 29363-29368, August 16, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/33/29363    most recent
M203495200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, Z.
Right arrow Articles by Chen, Y.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, Z.
Right arrow Articles by Chen, Y.-G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Transforming Growth Factor beta  Activates Smad2 in the Absence of Receptor Endocytosis*

Zhongxian LuDagger , James T. Murray§, Wenjie Luo, Hongling LiDagger , Xiaoping WuDagger ||, Huaxi Xu, Jonathan M. Backer§, and Ye-Guang ChenDagger ||**

From the Dagger  Division of Biomedical Sciences, University of California, Riverside, California 92521, § Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, and  Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021

Received for publication, April 11, 2002, and in revised form, May 22, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Like many other cell surface receptors, transforming growth factor beta  (TGF-beta ) receptors are internalized upon ligand stimulation. Given that the signaling-facilitating molecules Smad anchor for receptor activation (SARA) and Hrs are mainly localized in early endosomes, it was unclear whether receptor internalization is required for Smad2 activation. Using reversible biotin labeling, we directly monitored internalization of the TGF-beta type I receptor. Our data indicate that TGF-beta type I receptor is endocytosed via a clathrin-dependent mechanism and is effectively blocked by depletion of intracellular potassium or by expression of a mutant dynamin (K44A). However, blockage of receptor endocytosis by these two means has no effect on TGF-beta -mediated Smad2 activation. Furthermore, TGF-beta -induced Smad2 activation was unaffected by inhibition of hVPS34 activity with wortmannin or inhibitory anti-hVPS34 antibodies. Finally, we demonstrated that Smad2 interacted with cell surface receptors and that a SARA binding-deficient Smad2 mutant was phosphorylated by the receptors. Thus, our findings suggest that receptor endocytosis is dispersible for TGF-beta -mediated activation of Smad2 and that this activation can be mediated by both SARA-dependent and -independent mechanisms.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Receptor endocytosis has long been regarded as an attenuation mechanism to switch off receptor signaling. However, accumulating evidence suggests that endocytosis may facilitate signaling by targeting signaling complexes to specific subcellular localization, either to increase access of activated receptor kinases to their substrates or to compartmentalize signaling complexes (1-3). Consistent with this idea, blocking of clathrin-mediated endocytosis was found to attenuate the activation of the extracellular signal-regulated kinases by receptor tyrosine kinases and G-protein-coupled receptors (4-7). Upon the activation of G-protein-coupled proteinase-activated receptor 2, a multiprotein signaling complex that contains beta -arrestin 1, Raf-1, and extracellular signal-regulated kinases is formed on endocytic vesicles as well (8).

TGF-beta 1 binds to its cell surface receptors, resulting in the formation of type I and type II receptor complexes. In the complex, the TGF-beta type II receptor (Tbeta RII) phosphorylates and activates the TGF-beta type I receptor (Tbeta RI), which in turn phosphorylates the C-terminal serine residues of Smad proteins Smad2 and Smad3. As a result, Smad proteins accumulate in the nucleus, bind to DNA, and regulate transcription. The ligand-stimulated receptor complexes undergo endocytosis and are eventually degraded in an ubiquitin/lysosome-dependent pathway (9, 10).

The FYVE domain-containing proteins Smad anchor for receptor activation (SARA) and Hrs (the hepatocyte growth factor-regulated tyrosine kinase substrate) have been suggested to facilitate Smad2 phosphorylation by bringing Smad2 to TGF-beta or activin receptors (11, 12). Interestingly, immunofluorescence studies revealed that both SARA and Hrs are predominantly localized in early endosomes (11, 13). This finding raises an important question: does Smad2 phosphorylation occur at the plasma membrane, where the receptors are exposed to TGF-beta , or in early endosomes, where the signal-facilitating molecules SARA and Hrs are mainly localized? To investigate the role of TGF-beta receptor endocytosis in Smad2 activation, we directly followed endocytosis of Tbeta RI using a cell surface biotinylation protocol. Our data reveal that Tbeta RI is rapidly internalized via clathrin-mediated endocytosis but that inhibition of receptor internalization does not block Smad2 activation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Materials-- L17-Tbeta RI cells and HeLa cells stably expressing wild-type and K44A dynamin were maintained as described previously (14, 15). TGF-beta 1 was purchased from R&D Systems, wortmannin was purchased from Sigma, anti-phospho-Smad2 antibody was purchased from Upstate Biotechnology, anti-phospho-Thr308-AKT and anti-AKT were purchased from Cell Signaling Technology, and other antibodies were purchased from Santa Cruz Biotechnology. Anti-VPS34 antibodies have been described previously (22). Unless indicated, all chemicals were from Fisher/ICN. SARA(dFYVE) and SARA(665-end) were generated by PCR-based deletion, and the sequences were confirmed by DNA sequencing.

Transfection, reporter assay, immunoprecipitation, Western analysis, and immunofluorescence microscopy were performed as described previously (16). Receptor affinity labeling was carried out as described previously (17), except that 5 mM KCl was not included in KRH buffer for -KCl samples.

Depletion of Intracellular Potassium-- Potassium depletion was performed as described by Larkin et al. (18). Cells were treated with hypotonic medium (50% Dulbecco's modified Eagle's medium plus 50% H2O) for 10 min and with isotonic buffer (10 mM Tris, pH 7.5, 150 mM NaCl) with or without 10 mM KCl for 30 min. TGF-beta 1 was then added to a final concentration of 100 pM, and the cells were incubated for another 30 min. Cell lysates were harvested for Western analysis.

Biotinylation and Receptor Endocytosis-- L17-Tbeta RI cells were maintained in growth medium in the absence of tetracycline for 16-24 h before biotinylation. Biotinylation was performed as described previously (19). After labeling with 0.5 mg/ml NHS-SS-biotin (Pierce), the cells were shifted to 37 °C for the indicated time in the presence or absence of 100 pM TGF-beta 1. Endocytosis was then stopped by transferring cells back to 4 °C. After treatment with reducing solution (15.5 mg/ml glutathione, 75 mM NaCl, 75 mM NaOH, and 10% fetal bovine serum) and 5 mg/ml iodoacetamide (Sigma) in phosphate-buffered saline containing 0.8 mM MgCl2, 1.0 mM CaCl2 plus 1% bovine serum albumin, the cells were lysed in TNE (10 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, and 1 mM EDTA). Equal amounts of cell lysates were used for precipitation of biotinylated proteins with streptavidin beads (Pierce). Precipitated proteins were eluted and analyzed by immunoblotting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Rapid Clathrin-dependent Internalization of Tbeta RI-- To study the relationship between receptor signaling and endocytosis, we chose to directly monitor Tbeta RI internalization in the stable cell line L17-Tbeta RI that is derived from the Tbeta RI-deficient mink lung epithelial L17 cells and expresses HA-tagged Tbeta RI under the control of tetracycline (15). Cell surface proteins were labeled at 4 °C using a reducible biotinylation method (19). After additional incubation of labeled cells for various times at 37 °C, biotin remaining at the cell surface was removed by incubation with impermeable reducing agents at 4 °C. Internalized receptors, which are protected from reduction, were then precipitated with streptavidin beads and analyzed by immunoblotting.

First, we examined the ligand dependence of Tbeta RI internalization. The cell surface Tbeta RI was well labeled, and treatment of the cells with reducing agents efficiently removed biotin from the cell surface (Fig. 1A, lanes 1 and 2). After the cells were shifted to 37 °C, Tbeta RI was rapidly internalized, and its internalization was further increased by TGF-beta treatment (Fig 1A, lanes 3-8; Fig. 1B).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 1.   Rapid internalization of Tbeta RI. A, L17-Tbeta RI cells were biotin-labeled at 4 °C and then incubated at 37 °C with or without 100 pM TGF-beta 1 for the indicated time. The cells were transferred back to 4 °C and treated with a reducing buffer. Biotinylated Tbeta RI was isolated with streptavidin beads and analyzed by anti-HA immunoblotting. One representative experiment is shown here. Lane 1 (TL), total labeled cell surface Tbeta RI; lane 2 (BG), reducing control; lanes 3-5 (-TGFb), internalized Tbeta RI in the absence of TGF-beta 1; lanes 6-8 (+TGFb), internalized Tbeta RI in the presence of TGF-beta . B, quantitation of Tbeta RI internalization. The bands were scanned and quantitated using NIH Image 1.6. The internalized Tbeta RI is expressed as a percentage of total labeled Tbeta RI (total labeled = 100%) after subtraction of the background in the reducing control. The data were obtained from three independent experiments.

To examine whether Tbeta RI endocytosis is a clathrin-mediated process, we used two protocols that have been previously demonstrated to disrupt clathrin-mediated vesicle formation. Depletion of intracellular potassium decreases clathrin-coated pit formation and thus inhibits clathrin-dependent endocytosis (18). Clathrin-mediated endocytosis is also regulated by the GTPase dynamin, and expression of dynamin mutants defective in GTP binding or hydrolysis blocks the endocytosis of transferrin and epidermal growth factor receptors (20).

L17-Tbeta RI cells were treated with hypotonic medium followed by isotonic potassium-free buffer to deplete intracellular potassium. Potassium depletion significantly inhibited Tbeta RI endocytosis (Fig. 2A, lane 4). However, ligand-mediated Tbeta RI endocytosis was restored when 10 mM KCl was included in the buffer (Fig. 2A, lane 5). Therefore, depletion of intracellular potassium potently blocked Tbeta RI internalization.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 2.   Tbeta RI is internalized via a clathrin-mediated pathway. A, potassium depletion blocks Tbeta RI endocytosis. L17-Tbeta RI cells were subjected to potassium depletion (lane 4, -K) or to control treatment with 10 mM KCl included (lane 5, +K) for 30 min. The cells were then labeled with biotin, and internalization was performed in the presence of TGF-beta 1 at 37 °C for 30 min. Data are representative of four experiments. B, Tbeta RI internalization is inhibited by expression of K44A dynamin. HeLa cells expressing wild-type dynamin (WT Dyn) or K44A mutant (K44A) were transfected with HA-tagged Tbeta RI. After induction of dynamin expression, Tbeta RI internalization was examined. TL, total labeled cell Tbeta RI; BG, reducing control; -T, internalized Tbeta RI in the absence of TGF-beta 1; +T, internalized Tbeta RI in the presence of TGF-beta 1. Data are representative of three experiments.

To confirm the clathrin dependence of Tbeta RI internalization, we employed stable HeLa cell lines that express wild-type dynamin or the K44A mutant under the control of tetracycline (14); dynamin expression in these cells is induced by the withdrawal of tetracycline. The cells were transfected with HA-tagged Tbeta RI and maintained in the growth medium in the absence of tetracycline, and Tbeta RI endocytosis was measured. As shown in Fig. 2B, Tbeta RI is efficiently endocytosed in HeLa cells expressing wild-type dynamin (lanes 3 and 4); a high level of ligand-independent Tbeta RI internalization was observed, which could be due to the high level of receptor expression. Nonetheless, expression of K44A dynamin completely blocked Tbeta RI internalization (Fig. 2B, lanes 7 and 8).

Smad2 Activation Is Unaffected by Inhibition of Tbeta RI Endocytosis-- To test whether internalization of TGF-beta receptors is required for Smad activation, L17-Tbeta RI cells were subjected to depletion of intracellular potassium. The cells were then stimulated with TGF-beta , and Smad2 phosphorylation was detected by immunoblotting with anti-phospho-Smad2 antibodies (Fig. 3A). Although potassium depletion potently inhibited Tbeta RI internalization, it had no effect on TGF-beta -mediated Smad2 phosphorylation (compare lanes 4 and 6). Similar results were obtained with TGF-beta 1 at a concentration as low as 10 pM and were also observed in HeLa and Hep3B cells (data not shown).


View larger version (71K):
[in this window]
[in a new window]
 
Fig. 3.   Smad2 activation is independent of receptor endocytosis. A, L17-Tbeta RI cells were subjected to potassium depletion (-KCl) or control treatment (+KCl) for 30 min, followed by TGF-beta 1 treatment for another 30 min. Smad2 phosphorylation (top panel) and protein expression (bottom panel) were analyzed by immunoblotting with anti-phospho-Smad2 and anti-Smad2 antibodies, respectively. B, after tetracycline withdrawal for 16 h, parental and dynamin-expressing HeLa cells were treated with or without 100 pM TGF-beta 1 for 30 min. Smad2 phosphorylation was examined by anti-phospho-Smad2 immunoblotting (top panel). Smad2 protein expression was confirmed by anti-Smad2 (middle panel), and dynamin expression was confirmed by anti-HA immunoblotting (bottom panel). C, HeLa cells were continuously maintained in the medium containing tetracycline or subjected to tetracycline withdrawal for 16 h, and then they were treated with or without 100 pM TGF-beta 1 for 30 min. Intracellular localization of Smad2 was examined by immunofluorescence. Similar results were obtained from three different experiments. D, transcriptional activity of TGF-beta does not require clathrin-mediated endocytosis. HeLa cells were transfected with the 3TP-luciferase construct (left panel), and Hep3B cells were transfected with ARE-luciferase and FAST2 as well as various forms of dynamin constructs (right panel). After TGF-beta 1 treatment for 20 h, luciferase activity was determined. Relative luciferase activity (RLU) is expressed as the mean ± S.D. from triplicates. Similar results were obtained from three different experiments.

To further study whether clathrin-mediated endocytosis is essential for Smad2 activation by TGF-beta , we examined Smad2 phosphorylation in dynamin-expressing HeLa cells. TGF-beta stimulated the phosphorylation of Smad2 in parental HeLa cells (Fig. 3B, lanes 1 and 2), and this phosphorylation was not inhibited by the expression of wild-type or K44A dynamin (Fig. 3B, lanes 3-10). We also examined the effect of wild-type and mutant dynamin on TGF-beta -induced nuclear accumulation of Smad2. Smad2 is localized in the cytoplasm at the basal state, and TGF-beta treatment resulted in its translocation into the nucleus (Fig. 3C). Expression of either wild-type or K44A dynamin had no effect on TGF-beta -induced nuclear accumulation of Smad2 (Fig. 3C).

To examine whether Tbeta RI endocytosis is necessary for the transcriptional activity of TGF-beta , we examined the expression of two TGF-beta -responsive reporters (3TP-luciferase and ARE-luciferase), whose expression is Smad-mediated. The 3TP-luciferase construct was transiently transfected into parental or dynamin-expressing HeLa cells, and reporter expression was measured after TGF-beta treatment. TGF-beta -induced expression of this reporter was not inhibited by expression of either wild-type dynamin or K44A mutant (Fig. 3D, left panel). We further confirmed this result in Hep3B cells using the ARE-luciferase reporter. Expression of wild-type dynamin enhanced ARE-luciferase expression, which is consistent with slightly higher Smad2 phosphorylation in cells expressing wild-type dynamin (Fig. 3B, lane 6). However, expression of the T65A and K142A dynamin mutants, which have been shown to block transferrin uptake (21), did not inhibit TGF-beta induction of the ARE reporter (Fig. 3D, right panel). Taken together, these data strongly suggest that Tbeta RI endocytosis is not required for Smad2 activation or Smad-mediated reporter expression in TGF-beta -stimulated cells.

Inhibition of hVPS34p Activity Has No Effect on Smad2 Activation-- The FYVE domain of SARA binds to PI(3)P, and deletion of the FYVE domain-containing N terminus of SARA antagonizes TGF-beta -stimulated expression of ARE-luciferase (11). These data suggest that production of PI(3)P, presumably in the early endosome, is important for Tbeta RI signaling. To test this hypothesis, we treated L17-Tbeta RI cells with 100 nM wortmannin, which inhibits all phosphatidylinositol 3-kinases except the class II phosphatidylinositol 3-kinase C2alpha isoform. As shown in Fig. 4A, wortmannin had no effect on TGF-beta -stimulated Smad2 phosphorylation (lane 3), although it inhibited insulin-mediated Akt/protein kinase B phosphorylation at threonine 308 (lane 10). Similar results were obtained in Hep3B cells (data not shown). In addition, treatment of Hela cells with wortmannin did not affect TGF-beta -induced Smad2 nuclear localization (data not shown).


View larger version (113K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of hVPS34 activity has no effect on Smad2 activation. A, wortmannin does not interfere with TGF-beta -induced Smad2 phosphorylation. L17-Tbeta RI cells were treated with 100 nM wortmannin (Wort) or solvent DMSO (-) for 30 min, followed by stimulation with 100 pM TGF-beta 1 (Tb) or 100 nM insulin (Ins) for another 30 min. Smad2 phosphorylation was examined by anti-phospho-Smad2 immunoblotting (left panels), and AKT phosphorylation was examined with anti-phospho-Thr308-AKT (right panels). Protein expression is shown in the bottom panels. B, TGF-beta -mediated nuclear accumulation of Smad2 is unaffected by anti-hVPS34 inhibitory antibodies. HepG2 cells were microinjected with anti-hVPS34 antibodies (d) or control IgG (c) and treated with TGF-beta 1 for 30 min (b-d). The cells were stained with anti-Smad2 antibodies. Asterisks indicate injected cells. The data are representative of four separate experiments.

To specifically examine the role of PI(3)P in TGF-beta signaling, we microinjected HepG2 cells with specific inhibitory antibodies against the class III phosphatidylinositol 3-kinase, hVPS34. These antibodies disrupt the trafficking of internalized platelet-derived growth factor receptors and the endosomal localization of EEA1 (22). Moreover, they completely disrupt the localization of the intracellular PI(3)P marker 2X-FYVE-GFP fusion protein in Chinese hamster ovary (23) and HepG2 cells (data not shown). However, microinjection of inhibitory anti-VPS34 antibodies had no effect on TGF-beta -stimulated nuclear accumulation of Smad2 in HepG2 cells (Fig. 4B).

To directly address whether the FYVE domain is required for SARA function, we examined TGF-beta -induced expression of 3TP-luciferase in the presence of SARA(dFYVE), a mutant that lacks the FYVE domain. This mutant was shown to lose a punctate subcellular localization but still interact with Smad2 (11). We reasoned that this mutant should have a dominant negative effect on TGF-beta signaling by sequestering Smad2 and Smad3 away from the membrane. However, like the wild-type SARA, SARA(dFYVE) has no effect on TGF-beta activity in mediating the expression of 3TP-luciferase. This is in contrast to SARA(665-end), a mutant lacking both the N terminus and the FYVE domain, which does inhibit TGF-beta function (Fig. 5) (11). These results suggest that interactions between SARA and intracellular PI(3)P are not required for Smad2 activation.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   L17-Tbeta RI cells were transfected with 3TP-luciferase construct with or without various forms of SARA constructs. After TGF-beta 1 treatment for 20 h, luciferase activity was determined. Relative luciferase activities are expressed as the mean ± S.D. from triplicates. Similar results were obtained from three different experiments.

Smad2 Is Recruited to the Receptor Complexes on the Plasma Membrane-- To address whether Smad2 is activated on the plasma membrane, the receptor-Smad2 complexes were examined when receptor endocytosis was blocked. COS1 cells transfected with FLAG-tagged Smad1 or Smad2, Tbeta RI, and Tbeta RII were subjected to potassium depletion and then incubated with 125I-TGF-beta 1 to label cell surface receptors. After treatment with a cross-linking reagent, receptor-Smad complexes were examined by anti-FLAG immunoprecipitation and visualized by SDS-PAGE and autoradiography. Because the interaction between Tbeta RI and Smad2 is transient, Smad2 stably associated with the receptors only when the kinase-deficient Tbeta RI mutant was expressed (Fig. 6A, lane 3). Importantly, Smad2 still interacted with TGF-beta receptor complex even when receptor endocytosis was inhibited by potassium depletion (lane 5), strongly indicating that Smad2 is recruited into receptor complexes on the plasma membrane.


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 6.   A, interaction of Smad2 with cell surface receptors. COS1 cells were transfected with the constructs expressing FLAG-tagged Smad, wild-type Tbeta RII, and wild-type (WT) or kinase-deficient (KR) Tbeta RI, as indicated. Forty h later, cells were subjected to potassium depletion (-KCl) or control treatment (+KCl). Subsequently, cells were incubated with 200 pM 125I-TGF-beta 1 and treated with the cross-linking reagent DSS. Smad-receptor complexes were isolated with anti-FLAG immunoprecipitation and visualized by SDS-PAGE and autoradiography (top panel). Total cell surface receptors were verified by analysis of total labeled receptors, and Smad proteins were verified by anti-FLAG immunoblotting. B, SARA-Smad2 interaction is not essential for Smad2 phosphorylation. Dynamin-expressing HeLa cells were transfected with the constructs as indicated. After tetracycline withdrawal for 16 h, the cells were treated with or without 100 pM TGF-beta 1 for 30 min. Smad2 phosphorylation was examined by anti-FLAG immunoprecipitation and anti-phospho-Smad2 immunoblotting (top panel). Smad2 protein expression was confirmed by anti-FLAG immunoblotting (bottom panel).

To further investigate the role of SARA in Smad2 activation, we examined phosphorylation of Smad2(N381S), a mutant deficient in SARA-binding (24), in dynamin(K44A)-expressing HeLa cells. FLAG-tagged Smad2(N381S) was transfected into dynamin(K44A))-expressing HeLa cells together with Tbeta RI and Tbeta RII constructs. After induction of dynamin K44A expression for 16 h, the cells were treated with TGF-beta 1, and Smad2(N381S) phosphorylation was revealed by anti-phospho-Smad2 immunoblotting after anti-FLAG immunoprecipitation. As shown in Fig. 6B, Smad2(N381S) was phosphorylated when coexpressed with TGF-beta receptors, and this phosphorylation was further stimulated by TGF-beta . Phosphorylation of Smad2(N381S) in the absence of TGF-beta could be due to protein overexpression. Nonetheless, these results demonstrate that SARA binding activity is not essential for receptor-mediated phosphorylation of Smad2. This phosphorylation is presumably mediated by the cell surface receptors because it is not abolished by inhibition of receptor endocytosis.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our finding that Tbeta RI is internalized via clathrin-mediated endocytosis is in agreement with the earlier studies, which utilized granulocyte macrophage colony-stimulating factor-TGF-beta chimeric receptors (25). The internalization of these chimeric receptors was abolished by potassium depletion. Furthermore, recent studies also suggest that internalization of Tbeta RII is clathrin-mediated (26). However, uptake of 125I-TGF-beta 1 was not blocked by chloroquine or transient expression of K44A dynamin (27). The mechanism of TGF-beta uptake may differ from that of Tbeta RI internalization because TGF-beta uptake can be mediated by different binding proteins, such as beta -glycan. Thus, TGF-beta uptake reflects the sum of internalized TGF-beta -bound proteins, some of which may utilize clathrin-independent internalization mechanisms.

SARA has been shown to play a role in Smad-mediated signaling. Given the endosomal localization of this protein, a model has emerged in which the internalization of Tbeta RI receptors into early endosomes facilitates interactions with SARA and enhances TGF-beta signaling. In this study, we have tested several aspects of this model. We demonstrate that Tbeta RI internalizes via coated vesicles. However, inhibition of this process using two different methods has no effect on Smad2 phosphorylation and nuclear translocation and has no effect on TGF-beta -stimulated transcription. Furthermore, we find that disruption of the interaction between PI(3)P and the SARA FYVE domain, either by inhibiting cellular phosphatidylinositol 3-kinases with wortmannin, by specifically inhibiting hVPS34 with antibodies, or by deleting the FYVE domain, has no effect on TGF-beta -mediated signaling. In addition, we provide evidence that Smad2 can be recruited directly to cell surface TGF-beta receptors. Therefore, we conclude that Tbeta RI endocytosis is qualitatively dispersible for Smad2 activation and that interactions between the FYVE domain of SARA and PI(3)P are not necessary for Smad2-mediated TGF-beta signaling. We further demonstrate that the SARA binding-deficient mutant Smad2(N381S) is still phosphorylated by activated TGF-beta receptors. This is consistent with our previous results showing that both wild-type Smad2 and Smad2(N381S) can stimulate ARE-luciferase expression, but only the activity of wild-type Smad2 is enhanced by SARA (24). Thus, receptor-mediated Smad2 activation is mediated by both SARA-dependent and -independent mechanisms.

Our results do not rule out the possibility that receptor endocytosis may contribute to the maximal activation of Smad2. Although not required for TGF-beta signaling, interactions with endosomal SARA could modulate the intensity or lifetime of TGF-beta signaling in the presence of submaximal levels of ligand. This is suggested by recent experiments in which a dominant negative Rab5 increases TGF-beta signaling presumably by influencing early endosomal dynamics (28). Indeed, we observed that overexpression of wild-type dynamin slightly enhanced Smad2 phosphorylation. This suggests that overexpression of wild-type dynamin may accelerate receptor endocytosis and thereby facilitate Smad2 activation. Alternatively, enhanced Smad2 phosphorylation may be due to endocytosis-independent effects of dynamin on other signaling pathways, as has been suggested for mitogenic and apoptotic signal transduction (29, 30).

Receptor endocytosis has been shown to be required for certain signaling pathways but not for others. For instance, isoproterenol-stimulated extracellular signal-regulated kinase activation is inhibited by K44A dynamin, whereas activation of adenylate cyclase and phospholipase C via trimeric G-proteins is unaffected (7). Similarly, blockage of insulin-like growth factor receptor internalization interferes with the Shc/mitogen-activated protein kinase pathway, but not with the insulin receptor substrate-1 pathway (6). In addition to the Smad pathway, TGF-beta has also been implicated to signal through other pathways, such as mitogen-activated protein kinases (reviewed in Ref. 31). It remains to be determined whether these signaling pathways are dependent on TGF-beta receptor endocytosis.

    ACKNOWLEDGEMENTS

We thank Boris Pasche for L17-Tbeta RI cells, Sandra L. Schmid for dynamin plasmids and cell lines, Harvey T. McMahon for dynamin plasmids, and Gerard Honig for technical support. We are also grateful to Celio Pouponnot and Katie DeFea for critical comments on the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant AG09464 (to H. X.), a Postdoctoral Fellowship from the Juvenile Diabetes Foundation (to J. T. M.), National Institutes of Health Grant GM55692 (to J. M. B.), and the Bugher Foundation and University of California Cancer Research Coordinating Committee (to Y.-G. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| Present address: Department of Biological Sciences, Tsinghua University, Beijing 100084, P. R. China.

** To whom correspondence should be addressed: Division of Biomedical Sciences, University of California, 1413 Webber Hall, Riverside, CA 92521. Tel.: 909-787-2039; Fax: 909-787-2055; E-mail: yeguang.chen@ucr.edu.

Published, JBC Papers in Press, May 28, 2002, DOI 10.1074/jbc.M203495200

    ABBREVIATIONS

The abbreviations used are: TGF-beta , transforming growth factor beta ; Tbeta RI, TGF-beta type I receptor; Tbeta RII, TGF-beta type II receptor; SARA, Smad anchor for receptor activation; PI(3)P, phosphatidylinositol 3-phosphate; HA, hemagglutinin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. McPherson, P. S., Kay, B. K., and Hussain, N. K. (2001) Traffic 2, 375-384[CrossRef][Medline] [Order article via Infotrieve]
2. Di Fiore, P. P., and De Camilli, P. (2001) Cell 106, 1-4[CrossRef][Medline] [Order article via Infotrieve]
3. Miller, W. E., and Lefkowitz, R. J. (2001) Curr. Opin. Cell Biol. 13, 139-145[CrossRef][Medline] [Order article via Infotrieve]
4. Vieira, A. V., Lamaze, C., and Schmid, S. L. (1996) Science 274, 2086-2089[Abstract/Free Full Text]
5. Ceresa, B. P., Kao, A. W., Santeler, S. R., and Pessin, J. E. (1998) Mol. Cell. Biol. 18, 3862-3870[Abstract/Free Full Text]
6. Chow, J. C., Condorelli, G., and Smith, R. J. (1998) J. Biol. Chem. 273, 4672-4680[Abstract/Free Full Text]
7. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688[Abstract/Free Full Text]
8. DeFea, K. A., Zalevsky, J., Thoma, M. S., Dery, O., Mullins, R. D., and Bunnett, N. W. (2000) J. Cell Biol. 148, 1267-1281[Abstract/Free Full Text]
9. Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., and Wrana, J. L. (2000) Mol. Cell 6, 1365-1375[CrossRef][Medline] [Order article via Infotrieve]
10. Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., and Miyazono, K. (2001) J. Biol. Chem. 276, 12477-12480[Abstract/Free Full Text]
11. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) Cell 95, 779-791[CrossRef][Medline] [Order article via Infotrieve]
12. Miura, S., Takeshita, T., Asao, H., Kimura, Y., Murata, K., Sasaki, Y., Hanai, J. I., Beppu, H., Tsukazaki, T., Wrana, J. L., Miyazono, K., and Sugamura, K. (2000) Mol. Cell. Biol. 20, 9346-9355[Abstract/Free Full Text]
13. Raiborg, C., Bache, K. G., Mehlum, A., Stang, E., and Stenmark, H. (2001) EMBO J. 20, 5008-5021[CrossRef][Medline] [Order article via Infotrieve]
14. Damke, H., Baba, T., Warnock, D. E., and Schmid, S. L. (1994) J. Cell Biol. 127, 915-934[Abstract/Free Full Text]
15. Pasche, B., Kolachana, P., Nafa, K., Satagopan, J., Chen, Y. G., Lo, R. S., Brener, D., Yang, D., Kirstein, L., Oddoux, C., Ostrer, H., Vineis, P., Varesco, L., Jhanwar, S., Luzzatto, L., Massague, J., and Offit, K. (1999) Cancer Res. 59, 5678-5682[Abstract/Free Full Text]
16. Chen, Y. G., Hata, A., Lo, R. S., Wotton, D., Shi, Y., Pavletich, N., and Massagué, J. (1998) Genes Dev. 12, 2144-2152[Abstract/Free Full Text]
17. Lo, R. S., Chen, Y. G., Shi, Y. G., Pavletich, N., and Massagué, J. (1998) EMBO J. 17, 996-1005[CrossRef][Medline] [Order article via Infotrieve]
18. Larkin, J. M., Brown, M. S., Goldstein, J. L., and Anderson, R. G. (1983) Cell 33, 273-285[CrossRef][Medline] [Order article via Infotrieve]
19. Marmorstein, A. D., Zurzolo, C., Le, Bivic, A., and Rodriguez-Boulan, E. (1998) in Cell Biology: A Laboratory Handbook (Celis, J. E., ed), 2nd Ed., Vol. 120 , p. 341, Academic Press, San Diego, CA
20. Hinshaw, J. E. (2000) Annu. Rev. Cell Dev. Biol. 16, 483-519[CrossRef][Medline] [Order article via Infotrieve]
21. Marks, B., Stowell, M. H., Vallis, Y., Mills, I. G., Gibson, A., Hopkins, C. R., and McMahon, H. T. (2001) Nature 410, 231-235[CrossRef][Medline] [Order article via Infotrieve]
22. Siddhanta, U., McIlroy, J., Shah, A., Zhang, Y., and Backer, J. M. (1998) J. Cell Biol. 143, 1647-1659[Abstract/Free Full Text]
23. Vieira, O. V., Botelho, R. J., Rameh, L., Brachmann, S. M., Matsuo, T., Davidson, H. W., Schreiber, A., Backer, J. M., Cantley, L. C., and Grinstein, S. (2001) J. Cell Biol. 155, 19-25[Abstract/Free Full Text]
24. Wu, G., Chen, Y. G., Ozdamar, B., Gyuricza, C. A., Chong, P. A., Wrana, J. L., Massague, J., and Shi, Y. (2000) Science 287, 92-97[Abstract/Free Full Text]
25. Anders, R. A., Arline, S. L., Dore, J. J., and Leof, E. B. (1997) Mol. Biol. Cell 8, 2133-2143[Abstract/Free Full Text]
26. Ehrlich, M., Shmuely, A., and Henis, Y. I. (2001) J. Cell Sci. 114, 1777-1786[Abstract]
27. Zwaagstra, J. C., El-, Alfy, M., and O'Connor-McCourt, M. D. (2001) J. Biol. Chem. 276, 27237-27245[Abstract/Free Full Text]
28. Panopoulou, E., Gillooly, D. J., Wrana, J. L., Zerial, M., Stenmark, H., Murphy, C., and Fotsis, T. (2002) J. Biol. Chem. 277, 18046-18052[Abstract/Free Full Text]
29. Whistler, J. L., and von Zastrow, M. (1999) J. Biol. Chem. 274, 24575-24578[Abstract/Free Full Text]
30. Fish, K. N., Schmid, S. L., and Damke, H. (2000) J. Cell Biol. 150, 145-154[Abstract/Free Full Text]
31. Massague, J., and Chen, Y. G. (2000) Genes Dev. 14, 627-644[Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Y.-G. Chen, Z. Wang, J. Ma, L. Zhang, and Z. Lu
Endofin, a FYVE Domain Protein, Interacts with Smad4 and Facilitates Transforming Growth Factor-beta Signaling
J. Biol. Chem., March 30, 2007; 282(13): 9688 - 9695.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Hartung, K. Bitton-Worms, M. M. Rechtman, V. Wenzel, J. H. Boergermann, S. Hassel, Y. I. Henis, and P. Knaus
Different Routes of Bone Morphogenic Protein (BMP) Receptor Endocytosis Influence BMP Signaling
Mol. Cell. Biol., October 15, 2006; 26(20): 7791 - 7805.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. C. Wilkes and E. B. Leof
Transforming Growth Factor beta Activation of c-Abl Is Independent of Receptor Internalization and Regulated by Phosphatidylinositol 3-Kinase and PAK2 in Mesenchymal Cultures
J. Biol. Chem., September 22, 2006; 281(38): 27846 - 27854.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
M. I Suszko and T. K Woodruff
Cell-specificity of transforming growth factor-{beta} response is dictated by receptor bioavailability.
J. Mol. Endocrinol., June 1, 2006; 36(3): 591 - 600.
[Abstract] [Full Text] [PDF]


Home page
Biophys. JHome page
L.-C. Wang, W. Xiong, J. Zheng, Y. Zhou, H. Zheng, C. Zhang, L.-H. Zheng, X.-L. Zhu, Z.-Q. Xiong, L.-Y. Wang, et al.
The Timing of Endocytosis after Activation of a G-Protein-Coupled Receptor in a Sensory Neuron
Biophys. J., May 15, 2006; 90(10): 3590 - 3598.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-L. Chen, S. S. Huang, and J. S. Huang
Cellular Heparan Sulfate Negatively Modulates Transforming Growth Factor-beta1 (TGF-beta1) Responsiveness in Epithelial Cells
J. Biol. Chem., April 28, 2006; 281(17): 11506 - 11514.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Gu, P. Jin, L. Zhang, X. Zhao, X. Gao, Y. Ning, A. Meng, and Y.-G. Chen
Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia
Blood, March 1, 2006; 107(5): 1951 - 1954.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. C. Wilkes, H. Mitchell, S. G. Penheiter, J. J. Dore, K. Suzuki, M. Edens, D. K. Sharma, R. E. Pagano, and E. B. Leof
Transforming Growth Factor-{beta} Activation of Phosphatidylinositol 3-Kinase Is Independent of Smad2 and Smad3 and Regulates Fibroblast Responses via p21-Activated Kinase-2
Cancer Res., November 15, 2005; 65(22): 10431 - 10440.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
J. Jullien and J. Gurdon
Morphogen gradient interpretation by a regulated trafficking step during ligand-receptor transduction
Genes & Dev., November 15, 2005; 19(22): 2682 - 2694.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. E. Runyan, H. W. Schnaper, and A.-C. Poncelet
The Role of Internalization in Transforming Growth Factor {beta}1-induced Smad2 Association with Smad Anchor for Receptor Activation (SARA) and Smad2-dependent Signaling in Human Mesangial Cells
J. Biol. Chem., March 4, 2005; 280(9): 8300 - 8308.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
L. Zhang, H. Zhou, Y. Su, Z. Sun, H. Zhang, L. Zhang, Y. Zhang, Y. Ning, Y.-G. Chen, and A. Meng
Zebrafish Dpr2 Inhibits Mesoderm Induction by Promoting Degradation of Nodal Receptors
Science, October 1, 2004; 306(5693): 114 - 117.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. H. Choi, J. B. Park, S. S. Bae, S. Yun, H. S. Kim, W.-P. Hong, I.-S. Kim, J. H. Kim, M. Y. Han, S. H. Ryu, et al.
Phospholipase C-{gamma}1 is a guanine nucleotide exchange factor for dynamin-1 and enhances dynamin-1-dependent epidermal growth factor receptor endocytosis
J. Cell Sci., August 1, 2004; 117(17): 3785 - 3795.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
Y. Zhou, S. Scolavino, S. F. Funderburk, L. F. Ficociello, X. Zhang, and A. Klibanski
Receptor Internalization-Independent Activation of Smad2 in Activin Signaling
Mol. Endocrinol., July 1, 2004; 18(7): 1818 - 1826.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
W. Chen, K. C. Kirkbride, T. How, C. D. Nelson, J. Mo, J. P. Frederick, X.-F. Wang, R. J. Lefkowitz, and G. C. Blobe
{beta}-Arrestin 2 Mediates Endocytosis of Type III TGF-{beta} Receptor and Down-Regulation of Its Signaling
Science, September 5, 2003; 301(5638): 1394 - 1397.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract